       |
Campbell, Ca., January 29, 2007 - Hunter Labs Introduces FocalPoint™ Cytology for the Detection of Cervical Cancer
Hunter Laboratories, Inc., announced today that it's introducing the BD SurePath™ FocalPoint Cytology system for cervical cancer screening.
The SurePath FocalPoint imaging system technology improves cervical cancer screening performance and efficiency.
SurePath is the only Pap test with an FDA-approved claim of a 64.4% increase in HSIL+ detection. When SurePath pap slides are coupled with the FocalPoint imaging system there's an even greater reduction in false negatives.
The system utilizes the simplest and most proficient collection device on the market. SurePath also has the lowest rate for unsatisfactory specimens that require another sample for processing.
“Hunter laboratories is committed to providing our patients with the best new technology to detect disease early and the SurePath FocalPoint system allows us to do just that,” said Chris Riedel, CEO of Hunter Labs.
The FocalPoint system helps cytotechnologists reduce false negatives by prioritizing slides based on likelihood of abnormality.
Hunter Laboratories has partnered with Path Logic, one of Northern California's renowned pathology groups, to assist with the new technology.
Path Logic has eleven board certified pathologists in multiple specialties. Among these pathologists is, Dr. Stephen Bauer, who was chosen by the College of American Pathologists as Pathologist of the Year in 1999.
Related Outside Articles
Comparison of the effectiveness of two liquid-based Papanicolaou systems in the handling of adverse limiting factors, such as excessive blood
Direct-to-vial comparison of a new liquid-based cytology system, liqui-PREPTM versus the conventional Pap smear
Comparison of the SurepathTM liquid-based Papanicolaou smear with the conventional Papanicolaou smear in a multisite direct-to-vial study
Test Order Codes
1826 SurePath PAP with HPV
1821 SurePath PAP, reflex HPV on ASC-US & above
1822 SurePath PAP, reflex on ASC-US only
